Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127751151 | 12775115 | 1 | I | 20160918 | 0 | 20160921 | 20160921 | DIR | FDA-CTU | 60.00 | YR | F | N | 75.93000 | KG | 20160921 | N | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127751151 | 12775115 | 1 | PS | cetuximab | CETUXIMAB | 1 | Intravenous (not otherwise specified) | CETUXIMAB 250 MG/M2 INTRAVENOUS | 0 | 250 | DF | ||||||||
| 127751151 | 12775115 | 2 | SS | PALBOCICLIB | PALBOCICLIB | 1 | Oral | PALBOCICLIB 125MG PO QD DL-21/28 | 0 | 125 | MG | QD | |||||||
| 127751151 | 12775115 | 4 | C | BENZONATATE. | BENZONATATE | 1 | 0 | ||||||||||||
| 127751151 | 12775115 | 6 | C | COMPAZINE | PROCHLORPERAZINE MALEATE | 1 | 0 | ||||||||||||
| 127751151 | 12775115 | 8 | C | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 127751151 | 12775115 | 10 | C | LISINOPRIL. | LISINOPRIL | 1 | 0 | ||||||||||||
| 127751151 | 12775115 | 12 | C | MINOCYCLINE | MINOCYCLINEMINOCYCLINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 127751151 | 12775115 | 14 | C | PROCHLORPERAZINE. | PROCHLORPERAZINE | 1 | 0 | ||||||||||||
| 127751151 | 12775115 | 16 | C | TEMAZEPAM. | TEMAZEPAM | 1 | 0 | ||||||||||||
| 127751151 | 12775115 | 18 | C | TRIAMCINOLONE | TRIAMCINOLONE | 1 | 0 | ||||||||||||
| 127751151 | 12775115 | 20 | C | XANAX | ALPRAZOLAM | 1 | 0 | ||||||||||||
| 127751151 | 12775115 | 22 | C | FAMOTIDINE. | FAMOTIDINE | 1 | 0 | ||||||||||||
| 127751151 | 12775115 | 24 | C | MAGNESIUM | MAGNESIUM | 1 | 0 | ||||||||||||
| 127751151 | 12775115 | 26 | C | OXYCODONE | OXYCODONE | 1 | 0 | ||||||||||||
| 127751151 | 12775115 | 28 | C | POTASSIUM CHLORIDE. | POTASSIUM CHLORIDE | 1 | 0 | ||||||||||||
| 127751151 | 12775115 | 30 | C | AUGMENTIN | AMOXICILLINCLAVULANATE POTASSIUM | 1 | 0 | ||||||||||||
| 127751151 | 12775115 | 32 | C | PREDNISONE. | PREDNISONE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127751151 | 12775115 | 1 | Squamous cell carcinoma of head and neck |
| 127751151 | 12775115 | 2 | Squamous cell carcinoma of head and neck |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127751151 | 12775115 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127751151 | 12775115 | Blood magnesium decreased | |
| 127751151 | 12775115 | Dyspnoea | |
| 127751151 | 12775115 | Headache | |
| 127751151 | 12775115 | Mental status changes | |
| 127751151 | 12775115 | Nausea | |
| 127751151 | 12775115 | Oral infection | |
| 127751151 | 12775115 | Pneumonia | |
| 127751151 | 12775115 | Productive cough | |
| 127751151 | 12775115 | Pyrexia | |
| 127751151 | 12775115 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |